If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ASRT. There is no cost or obligation to you. NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential ...

Shares of Assertio Holdings, Inc. (ASRT) have nosedived 64.5% in the past three months against the industry’s increase of 17.6%.In January 2024, the company’s chief executive officer (CEO), Dan Peisert, stepped down from his role with immediate effect.Assertio appointed Heather Mason, who had already served as the independent director of the company, as its new interim CEO.Mason, who has been with Assertio since 2019, also served as the chair of its Nominating and Corporate Governance Committee.Assertio’s c ...

MediaProduction Investment thesis Okay, admitted: This one's a troubled child. At one point in 2015, the common stock of Assertio Holdings, Inc. (NASDAQ:ASRT) traded at ~$130. Less than a year later it had lost more than half of that value, and with the exception of a spike in late 2016, Assertio's share price has known only one way: Down. In addition to the poor performance on the stock exchange, Assertio caught the eye of Beckers Hospital Review which placed Assertio on its list of 31 drug makers at h ...

LAKE FOREST, Ill., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that effective January 2, 2024, the Compensation Committee of the Company's Board of Directors granted two newly-hired employee a total of 16,498 restricted stock units ("RSUs") and 18,654 stock options ("options"). The RSUs ...

Financial Data and Key Metrics Changes - Net product sales for Q3 2023 were $35.1 million, an increase from $34.3 million in the prior year but a decrease from $40.1 million in the previous quarter [17] - Adjusted EBITDA for Q3 was $12.9 million, down from $24.8 million last quarter and $21.4 million in the prior year quarter [21] - GAAP net loss for Q3 was $279.5 million compared to net income of $4.2 million in the prior year quarter, impacted by a $238.8 million impairment charge [25][24] Business Line Data and Key Metrics Changes - ROLVEDON generated $7.1 million in net product sales for the two months post-acquisition, with total sales of $8 million for Q3 [14][18] - INDOCIN family net sales decreased by 18% year-over-year due to generic competition [17] - Otrexup net sales were $2.8 million, down from $3 million in the prior year quarter, while Sympazan net sales increased by 4.2% to $2.1 million [19] Market Data and Key Metrics Changes - The net average selling price (ASP) decreased by 14% year-over-year due to short-term incentives previously offered to customers [19] - Inventory levels at the end customer level were approximately two months of demand at the end of Q3, down from four months at the end of Q2 [14] Company Strategy and Development Direction - The company is focused on stabilizing its base business and acquiring additional assets for diversification and long-term growth [8] - Management changes were announced to enhance oversight of market access, pricing, and distribution, indicating a strategic shift to improve operational efficiency [9] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in Q3 results but emphasized the importance of business transformation and the strength of the balance sheet [5][7] - The competitive landscape for INDOCIN has become more challenging due to the entry of generics and compounded products, impacting sales [11][12] Other Important Information - The company is not providing formal guidance but is committed to maximizing the long-term potential of ROLVEDON and other products [10][37] - A restructuring plan was implemented following the acquisition of Spectrum, which included $3 million in restructuring charges [24] Q&A Session Summary Question: Can you break down the impact of inventory adjustments on INDOCIN sales? - Management indicated they do not have a specific dollar amount for the inventory adjustment but acknowledged it was a factor in the decline [28][30] Question: What is the market share situation with the compounder and generic products? - Management stated they are tracking slightly below the expected erosion curve but are still within statistical control [31][32] Question: Were short-term incentives for ROLVEDON offered by Spectrum? - Yes, the incentives were offered by Spectrum and will not continue under Assertio [34] Question: What is the outlook for ROLVEDON sales? - Management is not providing specific estimates but is focused on maximizing the brand's long-term potential [36][37] Question: How active is the company in seeking additional deals? - The company is accelerating business development efforts and is well-positioned to capitalize on opportunities [40][42] Question: What is the current pricing situation for INDOCIN? - Pricing is impacted at the wholesaler level, with competitors offering lower prices, affecting Assertio's sales [63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF INC ...

Assertio Holdings Inc. (NASDAQ:ASRT) Q2 2023 Earnings Call Transcript August 3, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Dan Peisert - President and CEO Paul Schwichtenberg - Senior Vice President and CFO Tom Riga - Outgoing CEO of Spectrum Pharmaceuticals Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hamed Khorsand - BWS Financial Inc Jim Sidoti - SIDOTI & Company Scott Henry - Roth Capital Operator Good morning, and welcome to the Assertio Holdings In ...

Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief Executive Officer Paul Schwichtenberg - Senior Vice President & Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Scott Henry - ROTH Capital Hamed Khorsand - BWS Financial Mitra Ramgopal - Sidoti Operator Good afternoon and welcome to the Assertio Holdings' Fourth Quarter and Full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF (I ...